HMG-CoA Reductase

Bemfivastatin hemicalcium is an orally active inhibitor of HMG-CoA reductase (HMGCR), targeting cholesterol biosynthesis. This compound effectively promotes the liver's ability to extract lipids, leading to a significant reduction in blood lipid levels. Bemfivastatin hemicalcium is applicable in research on metabolic disorders, particularly in studying hypercholesterolemia and related conditions.

Lovastatin acid is a potent competitive inhibitor of HMG-CoA reductase, with an inhibition constant (Ki) of 0.6 nM. As an active metabolite of Lovastatin, it effectively interferes with cholesterol synthesis by inhibiting the conversion of HMG-CoA to mevalonate. This compound is particularly valuable for research into hypercholesterolemia and related metabolic disorders.

(3S,5S)-Pitavastatin calcium is a potent HMG-CoA reductase inhibitor effective in lowering cholesterol levels. It plays a significant role in the study of cardiovascular diseases by inhibiting lipid biosynthesis and improving lipid profiles. This compound is primarily utilized in research applications focused on atherogenesis and the investigation of statin therapy mechanisms.

Rosuvastatin zinc salt is a zinc-complexed form of Rosuvastatin, an HMG-CoA reductase inhibitor. This compound effectively reduces cholesterol synthesis, making it valuable in atherosclerosis research. Its mechanism of action supports studies focusing on lipid regulation and cardiovascular disease prevention.

BMS-180431 sodium is a potent inhibitor of HMG-CoA reductase, with an IC50 value of 43 nM. This compound plays a pivotal role in cholesterol biosynthesis, making it valuable for research focused on lipid metabolism and related cardiovascular diseases. Its inhibitory effects on HMG-CoA reductase provide a useful tool for studying cholesterol-lowering interventions and the underlying mechanisms of dyslipidemia.

L-645164 is a potent inhibitor of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase. This compound significantly reduces circulating serum cholesterol levels, demonstrating its efficacy in cholesterol management. Additionally, L-645164 shows potential for use in research related to central nervous system disorders, providing new avenues for investigation into therapeutic strategies.

PF-3052334 is a potent, orally available inhibitor of HMG-CoA reductase, exhibiting an IC50 of 1.9 nM. This compound selectively inhibits cholesterol synthesis in hepatocytes with an IC50 of 0.9 nM, while displaying a significantly higher IC50 of 730 nM in muscle cells. PF-3052334 serves as a valuable tool for investigating hypercholesterolemia and related metabolic disorders.

SQ-33600 is an HMG-CoA reductase inhibitor that exhibits cholesterol-lowering activity. It demonstrates significant selectivity, showing a much stronger inhibitory effect on rat hepatocytes (IC50: 93 nM) compared to human skin fibroblasts (IC50: 14200 nM). This compound is valuable for research on hypercholesterolemia and related metabolic disorders.

Crilvastatin is a potent HMG-CoA reductase inhibitor that plays a critical role in cholesterol biosynthesis regulation. By inhibiting this key enzyme, Crilvastatin effectively lowers cholesterol levels, making it valuable for research in dyslipidemia and cardiovascular disease. This compound serves as a useful tool in studies aimed at understanding lipid metabolism and the therapeutic potential of statins in managing hyperlipidemic conditions.

(3R,5R)-Rosuvastatin Lactone is an HMG-CoA reductase inhibitor that plays a crucial role in cholesterol biosynthesis modification. This compound exhibits potent lipid-lowering effects, making it valuable for studying dyslipidemia and related cardiovascular diseases. Its applications extend to elucidating mechanisms of action in statin therapies and examining its impact on metabolic pathways.